We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Herantis Pharma

News List

Herantis Pharma to develop non-invasive CDNF for Parkinson’s pharmaceutical-technology
July 12, 2018
Finnish drug development firm Herantis Pharma has launched a new programme for the development of a non-invasive cerebral dopamine neurotrophic factor (CDNF) to treat patients with Parkinson’s disease.
Herantis Pharma announces positive interim data from Lymfactin study in secondary lymphedema firstwordpharma
April 17, 2018
Herantis pharmaceuticals today announced the positive results from the 1 phase of clinical research.
Herantis Pharma Plc publishes introductory video on its Lymfactin with the leading lymphedema advoca firstwordpharma
January 24, 2017
Herantis Pharma Plc ("Herantis") has published an introductory video explaining the mechanism of its innovative drug candidate Lymfactin®, which it develops as a disease modifying treatment for lymphedema.